Compare CTSO & DARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTSO | DARE |
|---|---|---|
| Founded | 1997 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.9M | 19.2M |
| IPO Year | 2008 | 2014 |
| Metric | CTSO | DARE |
|---|---|---|
| Price | $0.39 | $0.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $5.38 | ★ $10.00 |
| AVG Volume (30 Days) | 58.7K | ★ 188.5K |
| Earning Date | 05-01-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 65.79 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $22,503,908.00 | $2,807,885.00 |
| Revenue This Year | $10.34 | $2,115.12 |
| Revenue Next Year | $22.41 | $122.62 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 48.53 | N/A |
| 52 Week Low | $0.35 | $1.13 |
| 52 Week High | $1.19 | $3.78 |
| Indicator | CTSO | DARE |
|---|---|---|
| Relative Strength Index (RSI) | 52.89 | 25.74 |
| Support Level | $0.36 | N/A |
| Resistance Level | $0.40 | $2.14 |
| Average True Range (ATR) | 0.03 | 0.14 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 80.00 | 16.31 |
CytoSorbents Corp is a leader in blood purification for the treatment of life-threatening conditions in the intensive care unit and cardiac surgery. CytoSorbent's proprietary blood purification technologies are based on biocompatible, high-porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbent's technologies are used in several broad applications. Specifically, two important applications are: the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and the removal of inflammatory agents and toxins in common critical illnesses that can cause massive inflammation, organ failure, and patient death. Geographically, in the USA, Germany, and Others.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.